chlormezanone 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 603 | 80-77-3 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A non-benzodiazepine that is used in the management of anxiety. It has been suggested for use in the treatment of muscle spasm.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 0.60 | g | O |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Hosey CM, Chan R, Benet LZ |
| BA (Bioavailability) | 99 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| May 20, 1960 | FDA |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Temperature regulation disorder | 526.58 | 110.14 | 101 | 2375 | 4126 | 50598522 |
| Food allergy | 460.62 | 110.14 | 101 | 2375 | 8036 | 50594612 |
| Coeliac disease | 448.55 | 110.14 | 100 | 2376 | 8585 | 50594063 |
| Immunodeficiency | 400.32 | 110.14 | 101 | 2375 | 14727 | 50587921 |
| Bursitis | 360.20 | 110.14 | 101 | 2375 | 22034 | 50580614 |
| Rash erythematous | 319.08 | 110.14 | 102 | 2374 | 34750 | 50567898 |
| Fluid retention | 277.94 | 110.14 | 101 | 2375 | 50548 | 50552100 |
| Upper respiratory tract infection | 248.59 | 110.14 | 100 | 2376 | 65798 | 50536850 |
| Hyperhidrosis | 228.72 | 110.14 | 103 | 2373 | 89323 | 50513325 |
| Asthma | 219.26 | 110.14 | 100 | 2376 | 89237 | 50513411 |
| Hepatic enzyme increased | 181.23 | 110.14 | 101 | 2375 | 137279 | 50465369 |
| Erythema | 180.62 | 110.14 | 103 | 2373 | 146311 | 50456337 |
| Constipation | 150.62 | 110.14 | 100 | 2376 | 185608 | 50417040 |
| Hypersensitivity | 144.20 | 110.14 | 103 | 2373 | 215058 | 50387590 |
| Back pain | 142.13 | 110.14 | 103 | 2373 | 219927 | 50382721 |
| Rheumatoid arthritis | 138.06 | 110.14 | 98 | 2378 | 202452 | 50400196 |
| Drug hypersensitivity | 127.86 | 110.14 | 102 | 2374 | 250908 | 50351740 |
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Temperature regulation disorder | 548.64 | 165.20 | 100 | 2288 | 4111 | 64492233 |
| Food allergy | 486.47 | 165.20 | 100 | 2288 | 7751 | 64488593 |
| Coeliac disease | 486.28 | 165.20 | 99 | 2289 | 7313 | 64489031 |
| Immunodeficiency | 414.80 | 165.20 | 100 | 2288 | 16024 | 64480320 |
| Bursitis | 386.29 | 165.20 | 100 | 2288 | 21385 | 64474959 |
| Rash erythematous | 313.69 | 165.20 | 102 | 2286 | 48531 | 64447813 |
| Fluid retention | 285.60 | 165.20 | 100 | 2288 | 59506 | 64436838 |
| Upper respiratory tract infection | 262.44 | 165.20 | 99 | 2289 | 72686 | 64423658 |
| Asthma | 236.64 | 165.20 | 99 | 2289 | 95126 | 64401218 |
| Hyperhidrosis | 213.93 | 165.20 | 100 | 2288 | 124820 | 64371524 |
| Hepatic enzyme increased | 210.16 | 165.20 | 100 | 2288 | 129843 | 64366501 |
| Erythema | 181.20 | 165.20 | 102 | 2286 | 186968 | 64309376 |
| Rheumatoid arthritis | 179.46 | 165.20 | 97 | 2291 | 164197 | 64332147 |
| Hypersensitivity | 179.23 | 165.20 | 103 | 2285 | 196349 | 64299995 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | M03BB02 | MUSCULO-SKELETAL SYSTEM MUSCLE RELAXANTS MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS Oxazol, thiazine, and triazine derivatives |
| ATC | M03BB52 | MUSCULO-SKELETAL SYSTEM MUSCLE RELAXANTS MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS Oxazol, thiazine, and triazine derivatives |
| ATC | M03BB72 | MUSCULO-SKELETAL SYSTEM MUSCLE RELAXANTS MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS Oxazol, thiazine, and triazine derivatives |
| CHEBI has role | CHEBI:35474 | anti-anxiety agents |
| CHEBI has role | CHEBI:35476 | neuroleptics |
| CHEBI has role | CHEBI:51371 | muscle relaxants |
| MeSH PA | D014151 | Anti-Anxiety Agents |
| MeSH PA | D002491 | Central Nervous System Agents |
| MeSH PA | D002492 | Central Nervous System Depressants |
| MeSH PA | D009125 | Muscle Relaxants, Central |
| MeSH PA | D009465 | Neuromuscular Agents |
| MeSH PA | D018373 | Peripheral Nervous System Agents |
| MeSH PA | D011619 | Psychotropic Drugs |
| MeSH PA | D014149 | Tranquilizing Agents |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Anxiety | indication | 48694002 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
None
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
None
External reference:
| ID | Source |
|---|---|
| 4018260 | VUID |
| N0000146590 | NUI |
| D00268 | KEGG_DRUG |
| 2373 | RXNORM |
| 4018260 | VANDF |
| C0008223 | UMLSCUI |
| CHEBI:3619 | CHEBI |
| CHEMBL1200714 | ChEMBL_ID |
| DB01178 | DRUGBANK_ID |
| D002720 | MESH_DESCRIPTOR_UI |
| 2717 | PUBCHEM_CID |
| 7323 | IUPHAR_LIGAND_ID |
| 782 | INN_ID |
| GP568V9G19 | UNII |
| 4413 | MMSL |
| d00909 | MMSL |
| 001447 | NDDF |
| 387400008 | SNOMEDCT_US |
| 71634000 | SNOMEDCT_US |
Pharmaceutical products:
None